OBJECTIVE: To compare socio-economic and health characteristics of HIV-infected patients in Côte d'Ivoire whether or not they had access to the Drug Access Initiative (DAI) and to antiretroviral drug (ARV) treatment. DESIGN AND METHODS: Cross-sectional survey using medical files, blood sampling for CD4 cell counts and face-to-face interviews among all patients, informed of their HIV status, who attended during a 6-week period in the five DAI referral centres and three additional centres in charge of HIV care in Abidjan and Bouaké (participation rate = 65.4%). Multiple logistic regression using generalized estimating equations (GEE) to identify factors related to non-access to DAI and to ARV treatment. RESULTS: Among the 711 respondents, 23.0% were ARV-treated, 14.2% had been included in the DAI but were still waiting for initiation of ARV, and 62.7% were neither part of the DAI nor ARV-treated. In this latter group, less than one-third (29.6%) declared that they knew about the existence of the DAI. Among the 164 ARV-treated patients, 59.1% had benefited from DAI public subsidies partially covering the costs of drugs. In the non-DAI-non-ARV-treated group, 86% could have qualified for ARV treatment according to the DAI medical criteria (CD4 cell counts < 500 x 10(6) cells/l), and only 32.9% of those medically eligible were prescribed cotrimoxazole prophylaxis. In multivariate analysis, not being in the DAI and not being ARV-treated was related to: being a male, not having health care insurance, having a low level of education, living in poor housing conditions (absence of refrigerator in the household, absence of ventilation in patient's bedroom), and not being under cotrimoxazole prophylaxis. CONCLUSION: The Ivoirian DAI has facilitated access to ARV treatment for a significant number of patients with limited ability to pay. The majority of HIV-infected patients seeking care however face persisting socio-economic and informational barriers to access to these treatments.
OBJECTIVE: To compare socio-economic and health characteristics of HIV-infectedpatients in Côte d'Ivoire whether or not they had access to the Drug Access Initiative (DAI) and to antiretroviral drug (ARV) treatment. DESIGN AND METHODS: Cross-sectional survey using medical files, blood sampling for CD4 cell counts and face-to-face interviews among all patients, informed of their HIV status, who attended during a 6-week period in the five DAI referral centres and three additional centres in charge of HIV care in Abidjan and Bouaké (participation rate = 65.4%). Multiple logistic regression using generalized estimating equations (GEE) to identify factors related to non-access to DAI and to ARV treatment. RESULTS: Among the 711 respondents, 23.0% were ARV-treated, 14.2% had been included in the DAI but were still waiting for initiation of ARV, and 62.7% were neither part of the DAI nor ARV-treated. In this latter group, less than one-third (29.6%) declared that they knew about the existence of the DAI. Among the 164 ARV-treated patients, 59.1% had benefited from DAI public subsidies partially covering the costs of drugs. In the non-DAI-non-ARV-treated group, 86% could have qualified for ARV treatment according to the DAI medical criteria (CD4 cell counts < 500 x 10(6) cells/l), and only 32.9% of those medically eligible were prescribed cotrimoxazole prophylaxis. In multivariate analysis, not being in the DAI and not being ARV-treated was related to: being a male, not having health care insurance, having a low level of education, living in poor housing conditions (absence of refrigerator in the household, absence of ventilation in patient's bedroom), and not being under cotrimoxazole prophylaxis. CONCLUSION: The Ivoirian DAI has facilitated access to ARV treatment for a significant number of patients with limited ability to pay. The majority of HIV-infectedpatients seeking care however face persisting socio-economic and informational barriers to access to these treatments.
Authors: Sylvie Boyer; Fabienne Marcellin; Pierre Ongolo-Zogo; Séverin-Cécile Abega; Robert Nantchouang; Bruno Spire; Jean-Paul Moatti Journal: Bull World Health Organ Date: 2009-04 Impact factor: 9.408
Authors: Louisa Jones; Paula Akugizibwe; Michaela Clayton; Joseph J Amon; Miriam Lewis Sabin; Rod Bennett; Christine Stegling; Rachel Baggaley; James G Kahn; Charles B Holmes; Navneet Garg; Carla Makhlouf Obermeyer; Christina DeFilippo Mack; Phoebe Williams; Caoimhe Smyth; Marco Vitoria; Siobhan Crowley; Brian Williams; Craig McClure; Reuben Granich; Gottfried Hirnschall Journal: Curr HIV Res Date: 2011-09 Impact factor: 1.581
Authors: Kate Groh; Carolyn M Audet; Alberto Baptista; Mohsin Sidat; Alfredo Vergara; Sten H Vermund; Troy D Moon Journal: BMC Public Health Date: 2011-08-16 Impact factor: 3.295
Authors: Linda M Richter; Knut Lönnroth; Chris Desmond; Robin Jackson; Ernesto Jaramillo; Diana Weil Journal: PLoS One Date: 2014-01-28 Impact factor: 3.240